Oral Tetrahydrocannabinol (THC):Cannabinoid (CBD) Cannabis Extract Adjuvant for Reducing Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial
Apichaya Sukpiriyagul,Ratiporn Chartchaiyarerk,Paluekpon Tabtipwon,Buppa Smanchat,Sinart Prommas,Kornkarn Bhamarapravatana,Komsun Suwannarurk
DOI: https://doi.org/10.2147/IJWH.S401938
2023-08-17
Abstract:Apichaya Sukpiriyagul, 1 Ratiporn Chartchaiyarerk, 1 Paluekpon Tabtipwon, 1 Buppa Smanchat, 1 Sinart Prommas, 1 Kornkarn Bhamarapravatana, 2 Komsun Suwannarurk 3 1 Department of Obstetrics and Gynecology, Bhumibol Adulyadej Hospital, Royal Thai Air Force Bangkok Thailand; 2 Department of Preclinical Science, Faculty of Medicine, Thammasat University Hospital, Pathum Thani, Thailand; 3 Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Thammasat University Hospital, Pathum Thani, Thailand Correspondence: Ratiporn Chartchaiyarerk, Department of Obstetrics and Gynecology, Bhumibol Adulyadej Hospital, Pathum Thani, Thailand, Tel +66814092569, Email Objective: To evaluate the effects of tetrahydrocannabinol (THC):cannabinoid (CBD) (1:1) oil in reducing chemotherapy-induced nausea and vomiting (CINV) in gynecologic cancer patients who received moderate-to-high emetogenic chemotherapy. Material and Method: This was a randomized, double-blinded, crossover and placebo-controlled trial. The study was conducted at the Gynecologic Oncology Units, Bhumibol Adulyadej Hospital (BAH), Royal Thai Air Force, Bangkok, Thailand, between August and November 2022. Participants had gynecologic cancer and received moderate-to-high emetogenic chemotherapy. Subjects were randomized and divided into two groups (A and B) based on the block of four randomization method. In the first cycle, groups A and B received THC:CBD extract oil 1:1 (TCEO) and placebo before chemotherapy administration. In the second cycle, groups A and B received placebo and TCEO before chemotherapy administration. Both groups received per protocol antiemetic medication during chemotherapy. Nausea score and side effects were recorded. Results: A total of 60 cases were recruited. After exclusion, 54 cases were included in the study. The mean age of participants was 54.4 years. The mean body mass index (BMI) was 26.5 kg/m 2 . Fifty-nine (21/54) percent cases were the advanced stages of cancer. The nausea score of TCEO and placebo groups were 2.11 and 2.99, respectively (P < 0.05). More than half of the participants (36/54) reported dizziness and sedation side effects. Dry mouth, confusion, anxiety, and palpitation of both groups were comparable. Conclusion: The cannabinoid extract (THC:CBD) was an appropriate adjuvant agent to reduce CINV in patients with gynecologic cancer who received high-emetogenic chemotherapy. Dizziness and sedation were the major side effects. Keywords: CINV, THC, CBD, cannabis Chemotherapy is an effective standard treatment for gynecologic malignancy. Despite the usefulness and efficacy of chemotherapy, it is still associated with numerous side effects, especially chemotherapy-induced nausea and vomiting (CINV). CINV is one of the most common adverse effects and leads to significant morbidity and deterioration of patients' quality of life. 1 As a consequence, noncompliance to chemotherapy treatment can be frequently observed. 2,3 CINV can be divided into five different phases: The acute phase is defined as CINV occurring within 24 h post chemotherapy, delayed phase is defined as CINV occurring within 24–120 h and may last 6–7 days, anticipatory phase is when patients have CINV prior to administration of future chemotherapy, breakthrough phase is when patients have CINV within 5 days of prophylactic antiemetic agents, and refractory phase is when CINV occurs in subsequent chemotherapy cycles following prior failure of prophylactic treatment. 4 Delayed phase is more common and severe than the other phases manner and is resistant to antiemetic treatment. 5 According to NCCN guidelines, standard antiemetic agents for patients receiving moderate and high emetogenic chemotherapy include 5-HT3 antagonists, dexamethasone, NK1 RAs, and olanzapine. However, NK1 RAs and olanzapine were added for patients receiving high emetic risk chemotherapy. Platinum-based chemotherapy (cisplatin and carboplatin) were the backbone of chemotherapy regimen in gynecologic cancer and were classified as high emetic risk. Lorazepam and a histamine (H2) blocker or a proton pump inhibitor may also be added to all these regimens to manage anxiety and dyspepsia/reflux-related symptoms, respectively. 4 Although the use of antiemetic agents have improved, CINV remains an issue with most patients. The endocannabinoid system is associated with the control of nausea and vomiting through cannabinoid receptors 1(CB1) and cannabinoid receptors 2 (CB2). CB1 receptors are mainly found in the central venous system and CB2 receptors are located mainly in the peripheral. Both CB1 and CB2 are found in the d -Abstract Truncated-
obstetrics & gynecology